Abingworth LLP

13F Filings History

Latest 13F report
Q2 2025 - Aug 8, 2025
Signature - Title
John Heard - General Counsel
Location
London, United Kingdom
Summary
This page shows a list of all the recent 13F filings made by Abingworth LLP. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Abingworth LLP reported 18 stock holdings with total value $304M as of Q4 2022. Top holdings included PCVX, VRNA, VERA, HLVX, and ACET. Carlyle Group Inc. is reporting for Abingworth LLP.
Holdings Value

Carlyle Group Inc. is reporting for Abingworth LLP:

Name Holdings Value Location File Number
Carlyle Group Inc. $5.03B Washington, DC 028-15025
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Date Filed
Q2 2025 13F-NT 8/8/2025, 05:18 PM
Q1 2025 13F-NT 5/9/2025, 04:48 PM
Q4 2024 13F-NT 2/13/2025, 05:03 PM
Q3 2024 13F-NT 11/8/2024, 05:00 PM
Q2 2024 13F-NT 8/9/2024, 04:47 PM
Q1 2024 13F-NT 5/3/2024, 04:39 PM
Q4 2023 13F-NT 2/2/2024, 04:47 PM
Q3 2023 13F-NT 11/3/2023, 04:44 PM
Q2 2023 13F-NT 8/4/2023, 04:41 PM
Q1 2023 13F-NT 5/5/2023, 05:01 PM
Q4 2022 18 $304M -$103M -$103M PCVX, VRNA, VERA, HLVX, ACET 13F-HR 2/10/2023, 03:28 PM
Q3 2022 19 $292M +$4.92M +$4.92M PCVX, VERA, HLVX, ACET, VRNA 13F-HR 11/10/2022, 03:48 PM
Q2 2022 21 $312M +$19.9M -$14.7M +$5.25M PCVX, SRRA, VERA, ACET, HLVX 13F-HR 8/15/2022, 06:30 AM
Q1 2022 20 $352M +$18.9M +$18.9M PCVX, VERA, ACET, SRRA, JSPR 13F-HR 5/16/2022, 07:00 AM
Q4 2021 20 $413M +$8.72M +$8.72M PCVX, VERA, JSPR, EFTR, ACET 13F-HR 2/16/2022, 10:26 AM
Q3 2021 20 $441M +$126M -$1.73M +$124M PCVX, EFTR, JSPRXXXX, VERA, PHAT 13F-HR 11/15/2021, 06:05 AM
Q2 2021 19 $324M +$56.7M $0 +$56.7M PCVX, PHAT, VERA, SIENXXXX, RPHM 13F-HR 8/16/2021, 06:30 AM
Q1 2021 17 $290M +$22.9M $0 +$22.9M PCVX, PHAT, ACET, VRNA, SIENXXXX 13F-HR 5/17/2021, 06:11 AM
Q4 2020 15 $292M +$43.1M -$86.4K +$43M PCVX, PHAT, SLNO, VRNA, NCNA 13F-HR 3/1/2021, 10:18 AM
Q3 2020 17 $468M +$27.3M -$43.1M -$15.8M PCVX, PSNL, PHAT, SLNO, CRSP 13F-HR 11/16/2020, 05:15 AM
Q2 2020 15 $355M +$139M +$139M PCVX, PSNL, PHAT, CRSP, SLNO 13F-HR 8/14/2020, 03:27 PM
Q1 2020 16 $151M +$9.09M +$9.09M PSNL, PHAT, CRSP, SLNO, XCUR 13F-HR 5/14/2020, 06:05 AM
Q4 2019 16 $207M +$48.9M -$6.65M +$42.3M PSNL, PHAT, CRSP, SIENXXXX, SLNO 13F-HR 2/14/2020, 05:05 AM
Q3 2019 14 $158M +$15.8M -$24M -$8.2M PSNL, CRSP, XCUR, SIENXXXX, SLNO 13F-HR 11/14/2019, 05:06 AM
Q2 2019 13 $261M +$148M -$12.6M +$135M PSNL, CRSP, SIENXXXX, AVDR, SLNO 13F-HR 8/14/2019, 06:09 AM
Q1 2019 14 $112M +$13.4M -$4.61M +$8.79M CRSP, SIENXXXX, CHMA, SLNO, AVDR 13F-HR 5/15/2019, 06:15 AM
Q4 2018 16 $110M +$7.98M -$3M +$4.98M CRSP, SIENXXXX, VRNA, SLNO, CHMA 13F-HR 2/14/2019, 05:16 AM
Q3 2018 16 $168M +$11.3M -$6.72M +$4.55M CRSP, SIENXXXX, VRNA, PRTK, OBSVF 13F-HR 11/14/2018, 05:15 AM
Q2 2018 16 $175M +$7.22M -$38.2M -$31M CRSP, SIENXXXX, PRTK, OBSVF, GTXI 13F-HR 8/14/2018, 07:00 AM
Q1 2018 16 $161M +$2.98M -$14.3M -$11.3M CRSP, SIENXXXX, PRTK, GTXI, OBSVF 13F-HR 5/15/2018, 06:08 AM
Q4 2017 17 $138M -$4.12M -$4.12M CRSP, SIENXXXX, PRTK, CBAY, OBSVF 13F-HR 2/14/2018, 05:10 AM
Q3 2017 18 $144M +$8.61M -$15.4M -$6.78M CRSP, SIENXXXX, PRTK, CBAY, CHMA 13F-HR 11/14/2017, 05:13 AM
Q2 2017 16 $126M -$2.53M -$2.53M CRSP, PRTK, SIENXXXX, CBAY, CASC 13F-HR 8/14/2017, 06:02 AM
Q1 2017 17 $134M +$6.72M -$926K +$5.8M CRSP, PRTK, SIENXXXX, CBAY, CASC 13F-HR 5/15/2017, 07:36 AM
Q4 2016 16 $118M +$53.2M -$1.76M +$51.4M CRSP, PRTK, SIENXXXX, NOVNXXXX, CHMA 13F-HR 2/14/2017, 05:04 AM
Q3 2016 20 $104M +$4.8M -$232K +$4.56M SIENXXXX, PRTO, PRTK, CEMP, CHMA 13F-HR 11/14/2016, 06:20 AM
Q2 2016 20 $95.5M +$4.78M +$4.78M PRTK, PRTO, SIENXXXX, TBRA, CEMP 13F-HR 8/12/2016, 06:03 AM
Q1 2016 19 $108M +$256K +$256K PRTK, CHMA, PRTO, SIENXXXX, CEMP 13F-HR 5/13/2016, 06:16 AM
Q4 2015 18 $166M +$6.11M -$249K +$5.86M CHMA, PRTO, PRTK, SIENXXXX, CEMP 13F-HR 2/16/2016, 06:22 AM
Q3 2015 17 $171M +$46.1M -$1.25M +$44.8M CHMA, PRTO, PRTK, SIENXXXX, EVAR 13F-HR 11/13/2015, 05:49 AM
Q2 2015 15 $216M +$19M -$3.65M +$15.3M SIENXXXX, PRTO, PRTK, AMRN, EVAR 13F-HR 8/14/2015, 06:47 AM
Q1 2015 17 $235M +$1.02M -$40.6M -$39.6M SIENXXXX, PRTK, SUPN, DRNA, PRTO 13F-HR 5/14/2015, 06:03 AM
Q4 2014 16 $352M +$108M +$108M RNA, PRTK, SIENXXXX, PTLA, SUPN 13F-HR 2/13/2015, 05:12 AM
Q3 2014 13 $167M +$25.7M -$14.1M +$11.6M RNA, EVAR, SUPN, PTLA, DRNA Restatement 11/25/2014, 02:07 PM
Q2 2014 12 $215M +$1.58M +$1.58M RNA, SUPN, PTLA, DRNA, AMRN 13F-HR 8/14/2014, 06:53 AM
Q1 2014 13 $181M +$36.3M +$36.3M RNA, DRNA, SUPN, PTLA, AMRN 13F-HR 5/20/2014, 06:33 PM
Q4 2013 11 $133M PTLA, RNA, SUPN, AMRN, CEMP 13F-HR 2/14/2014, 07:47 AM